Literature DB >> 18571834

Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors.

Raffaele Ciampi1, Agnese Vivaldi, Cristina Romei, Alberto Del Guerra, Piero Salvadori, Barbara Cosci, Aldo Pinchera, Rossella Elisei.   

Abstract

Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is based on cell capability to take-up glucose. While a significantly higher expression of the glucose transporter GLUT1 has been reported in thyroid tumors only few data are available on the expression of other GLUT isoforms. We studied several GLUT isoforms expression in thyroid tumor cell lines deriving from anaplastic (ARO, FRO), papillary (NPA), follicular (WRO) and medullary (TT) human thyroid carcinoma. GLUT1 and GLUT3 were also studied in 157 human thyroid malignant and benign tissues. Quantitative Real-time RT-PCR analysis revealed that GLUT1 mRNA levels were higher in less-differentiated cells (ARO, FRO) while GLUT3 mRNA levels were prevalent in well-differentiated cells (NPA, WRO). Accordingly, Western blot showed high expression and correct membrane targeting of GLUT1 protein in ARO and FRO and of GLUT3 protein in NPA and WRO. All cell lines were able to take-up different rates of (3)H-deoxy-glucose. The analysis of GLUT1 and GLUT3 mRNA expression in human thyroid tissues showed the prevalence of GLUT1, but not of GLUT3, in malignant with respect to normal tissues. Finally, both GLUT1 and GLUT3 showed a slightly higher expression in anaplastic than in well-differentiated tumors. In conclusion, we showed that GLUT1 and GLUT3 were the most important glucose transporters in the thyroid tumoral cells. In particular GLUT1 was the most prevalent in less-differentiated cells (ARO and FRO) while GLUT3 was the most prevalent in well-differentiated cells (NPA and WRO). A similar pattern of expression was found for GLUT1 but not for GLUT3 in human thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571834     DOI: 10.1016/j.mce.2008.05.003

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I.

Authors:  E Zoidis; C Ghirlanda-Keller; C Schmid
Journal:  Mol Cell Biochem       Date:  2010-11-13       Impact factor: 3.396

Review 2.  Designing polymers with sugar-based advantages for bioactive delivery applications.

Authors:  Yingyue Zhang; Jennifer W Chan; Alysha Moretti; Kathryn E Uhrich
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

3.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

4.  ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.

Authors:  Arnoldo Piccardo; Matteo Puntoni; Francesco Bertagna; Giorgio Treglia; Luca Foppiani; Federico Arecco; Raffaele Giubbini; Mehrdad Naseri; Angelina Cistaro; Manlio Cabria; Francesca Bardesono; Luca Ceriani; Fabio Orlandi; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-30       Impact factor: 9.236

5.  Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.

Authors:  Jeong Won Lee; Hye Sook Min; Sang Mi Lee; Hyun Woo Kwon; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2015-02-13

6.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

7.  Antitumoral activity of L-ascorbic acid-poly- D,L-(lactide-co-glycolide) nanoparticles containing violacein.

Authors:  Dorival Martins; Lucas Frungillo; Maristela C Anazzetti; Patrícia S Melo; Nelson Durán
Journal:  Int J Nanomedicine       Date:  2010-02-02

8.  The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma.

Authors:  Brian Hung-Hin Lang
Journal:  J Thyroid Res       Date:  2011-10-09

9.  Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer.

Authors:  Eun Jeong Ban; Daham Kim; Jin Kyong Kim; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Kunhong Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-02-24

10.  GLUT1 gene is a potential hypoxic marker in colorectal cancer patients.

Authors:  Fu-Yen Chung; Ming-Yii Huang; Ching-Sheng Yeh; Hui-Jen Chang; Tian-Lu Cheng; Li-Chen Yen; Jaw-Yuan Wang; Shiu-Ru Lin
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.